Tirzepatide (Zepbound)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Obesity

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Psoriasis · Phase 3Psoriatic Arthritis · Phase 3Crohn's Disease · Phase 3

Also approved (5)
US
  • Moderate to severe obstructive sleep apnea (OSA) in adults with obesity (Zepbound)FDA label
  • Zepbound: to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesityFDA label
Product first approved 2023
JP
  • Zepbound: obesity disease
Product first approved 2024pj.jiho.jp
EU
  • Mounjaro: weight management indication (extension)
EMA
CA
  • ZEPBOUND (tirzepatide injection) is indicated for once-weekly administration as an adjunct to a reduced-calorie diet and increased physical activity: • for chronic weight management, including weight loss and weight maintenance in adults with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obesity) or • 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight- related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). • to treat moderate to severe obstructive...
Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (28)
Crohn's Disease
NCT06937099 · Eli Lilly and Company
2025-06-26 – 2028-05 · Crohn's Disease, Obesity or Overweight
What this study did
Obesity
NCT06439277 · Eli Lilly and Company
2024-06-03 – 2030-12 · Obesity, Weight Gain
What this study did
NCT07881432 · Eli Lilly and Company
2026-12 – 2029-11 · Obesity
What this study did
NCT07881458 · Eli Lilly and Company
2026-10-16 – 2029-11 · Obesity, Overweight, Diabetes Mellitus, Type 2
What this study did
NCT06075667 · Eli Lilly and Company
2023-10-16 – 2029-07 · Obesity, Overweight
What this study did
NCT06937086 · Eli Lilly and Company
2025-06-26 – 2028-04 · Ulcerative Colitis, Obesity or Overweight
What this study did
NCT07481747 · Hudson Biotech
2026-02-02 – 2028-03-17 · Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
What this study did
NCT07738276 · Shahid Beheshti University of Medical Sciences
2026-07-18 – 2027-12-22 · Heart Failure and Reduced Ejection Fraction, Obesity & Overweight, Tirzepatide
What this study did
NCT05556512 · Eli Lilly and Company
2022-10-11 – 2027-10 · Obesity, Overweight
What this study did
NCT06962280 · Eli Lilly and Company
2025-05-12 – 2027-07 · Type 1 Diabetes, Obesity, Overweight
What this study did
NCT06914895 · Eli Lilly and Company
2025-04-25 – 2026-12 · Type 1 Diabetes, Obesity, Overweight
What this study did
NCT06918405 · Chittagong Medical College
2025-01-01 – 2026-06-30 · Obesity and Obesity-related Medical Conditions
What this study did
NCT07834398 · Zagazig University
2025-11-14 – 2026-04-21 · Non-diabetec Obesity, Obesity (Disorder)
What this study did
NCT07820111 · Zagazig University
2025-10-18 – 2026-03-17 · Obese Diabetics, Obese Non Diabetic
What this study did
NCT06047548 · Eli Lilly and Company
2023-09-20 – 2026-01-20 · Overweight, Obesity
What this study did
NCT05822830 · Eli Lilly and Company
2023-04-21 – 2024-11-13 · Obesity, Overweight
What this study did
NCT04847557 · Eli Lilly and Company
2021-04-20 – 2024-07-02 · Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
What this study did
NCT04844918 · Eli Lilly and Company
2021-05-10 – 2023-06-24 · Obesity
What this study did
NCT05024032 · Eli Lilly and Company
2021-09-01 – 2022-12-27 · Obesity, Overweight, Metabolism and Nutrition Disorder
What this study did
Psoriasis
NCT06588283 · Eli Lilly and Company
2024-09-30 – 2026-06-01 · Psoriasis, Obesity
What this study did
Psoriatic Arthritis
NCT06588296 · Eli Lilly and Company
2024-09-24 – 2026-04-23 · Psoriatic Arthritis, Obesity
What this study did
Phase 2/3 (2)
Obesity
NCT07846865 · Woolcock Institute of Medical Research
2026-10-01 – 2028-12-01 · Sleep Apnoea, Obesity & Overweight, Sleep Apnea Syndrome, Obstructive
What this study did
NCT06162715 · Vanderbilt University Medical Center
2024-10-30 – 2027-04-30 · Severe Obesity, Obesity, BMI Greater Than 30
What this study did
Phase 2 (30)
Obesity
NCT06517212 · Baylor Research Institute
2024-11-26 – 2030-12-31 · Breast Cancer, Breast Neoplasms, Breast Cancers
What this study did
NCT07349641 · National Cancer Institute (NCI)
2026-11-01 – 2030-10-31 · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
What this study did
NCT07693608 · University of Texas Southwestern Medical Center
2026-08-19 – 2030-03-01 · Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders
What this study did
NCT05912621 · Stanford University
2023-11-09 – 2029-12 · Obesity, Overweight and Obesity, Overweight
What this study did
NCT07747805 · The Cleveland Clinic
2026-08-28 – 2029-08-15 · COPD, Obesity & Overweight, Sarcopenia
What this study did
NCT06582875 · University of Colorado, Denver
2025-03-06 – 2029-06-30 · Autosomal Dominant Polycystic Kidney, Obesity
What this study did
NCT07078838 · UNC Lineberger Comprehensive Cancer Center
2027-01 – 2029-03 · Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma
What this study did
NCT06180616 · Royal North Shore Hospital
2026-12 – 2028-12 · Type 1 Diabetes Mellitus, Overweight and Obesity
What this study did
NCT07228741 · St. Jude Children's Research Hospital
2026-04-23 – 2028-11 · Acute Lymphoblastic Leukemia, Obesity
What this study did
NCT06143956 · Eli Lilly and Company
2023-11-17 – 2028-02 · Obesity, Overweight
What this study did
NCT07292519 · South West Sydney Local Health District
2026-01-15 – 2028-01-15 · Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions
What this study did
NCT06732245 · Biomed Industries, Inc.
2026-08-15 – 2027-12-15 · Obesity and Overweight
What this study did
NCT06847399 · Johns Hopkins University
2025-09-17 – 2027-12-01 · Obesity and Overweight, Binge Eating Disorder
What this study did
NCT07671391 · Shanghai Zhongshan Hospital
2026-08 – 2027-12 · Obesity Adult Onset
What this study did
NCT06518837 · Rutgers, The State University of New Jersey
2024-10-30 – 2027-09-30 · Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
What this study did
NCT06802081 · The Cleveland Clinic
2025-04-08 – 2027-06-01 · Atrial Fibrillation, Obesity
What this study did
NCT06811324 · The University of Texas Health Science Center at San Antonio
2026-04-01 – 2027-06-01 · Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
What this study did
NCT06965413 · Hoffmann-La Roche
2025-05-05 – 2027-03-31 · Obesity, Overweight, Overweight With One Weight Related Comorbidity
What this study did
NCT07179120 · First Affiliated Hospital of Wenzhou Medical University
2026-05-01 – 2027-01-02 · Obesity-related Male Infertility
What this study did
NCT06037252 · Eli Lilly and Company
2023-09-21 – 2026-10 · Type 2 Diabetes, Obesity
What this study did
NCT06994338 · University of Southern California
2025-10-06 – 2026-08-31 · Alcohol Use Disorder, Obesity and Overweight, Alcohol
What this study did
NCT05536804 · Eli Lilly and Company
2023-02-08 – 2026-07-30 · Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
What this study did
NCT06935838 · University of Hawaii
2025-11-12 – 2026-06-02 · Obesity and Overweight, HIV, Chronic Inflammation
What this study did
NCT06373146 · Eli Lilly and Company
2024-04-24 – 2026-04-02 · Obesity
What this study did
NCT06745128 · University of Texas Southwestern Medical Center
2025-02-03 – 2026-02-12 · Obesity, Methamphetamine Use Disorder
What this study did
NCT06893211 · University Medical Centre Ljubljana
2025-03-18 – 2025-12-20 · Obesity
What this study did
NCT06901349 · Eli Lilly and Company
2025-05-23 – 2025-06-10 · Obesity, Overweight
What this study did
NCT06565611 · Palatin Technologies, Inc
2024-08-05 – 2025-03-31 · Obesity
What this study did
Phase 1/2 (1)
Obesity
NCT07463846 · Alnylam Pharmaceuticals
2026-03-02 – 2028-04-28 · Obesity
What this study did
Phase 1 (19)
Obesity
NCT06759701 · M.D. Anderson Cancer Center
2025-07-02 – 2028-12-31 · Diabetes, Prostate Cancer
What this study did
NCT06734273 · Nicholas Skertich
2025-03-10 – 2028-09 · Obesity and Obesity-related Medical Conditions
What this study did
NCT07065552 · UNC Lineberger Comprehensive Cancer Center
2026-04-27 – 2028-07 · Endometrial Cancer, Obesity
What this study did
NCT06751589 · Memorial Sloan Kettering Cancer Center
2024-12-19 – 2027-12 · Endometrial Cancer
What this study did
NCT06575738 · University of Colorado, Denver
2024-10-11 – 2027-10-01 · Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
What this study did
NCT05822544 · OrsoBio, Inc
2023-04-22 – 2027-01 · Healthy Subjects, Obesity, Type 2 Diabetes
What this study did
NCT07803744 · Eli Lilly and Company
2026-09-11 – 2026-12 · Diabetes Mellitus, Type 1, Overweight, Obesity
What this study did
NCT06934642 · University of New Mexico
2025-06-30 – 2026-10 · MASLD, Obesity
What this study did
NCT06916065 · Eli Lilly and Company
2025-04-09 – 2026-01-19 · Overweight, Obesity
What this study did
NCT06297616 · Eli Lilly and Company
2024-04-15 – 2025-11-21 · Obesity, Overweight
What this study did
NCT06345066 · Eli Lilly and Company
2024-04-03 – 2025-09-29 · Obesity, Overweight
What this study did
NCT05696847 · Eli Lilly and Company
2023-02-07 – 2025-01-16 · Obesity
What this study did
NCT05582096 · Eli Lilly and Company
2022-11-11 – 2023-06-08 · Overweight, Obesity
What this study did
NCT04311411 · Eli Lilly and Company
2020-08-24 – 2022-12-16 · Obesity, Overweight
What this study did
NCT04081337 · Eli Lilly and Company
2020-07-09 – 2022-05-26 · Obesity
What this study did
NCT04407234 · Eli Lilly and Company
2020-09-15 – 2021-01-07 · Overweight, Obesity, Diabetes Mellitus, Type 2
What this study did
Phase 4 (28)
Obesity
NCT06191848 · University of Melbourne
2024-11-19 – 2037-05 · Obesity, Knee Osteoarthritis, Osteoarthritis, Knee
What this study did
NCT07247084 · Eli Lilly and Company
2025-11-24 – 2032-07 · Obesity
What this study did
NCT07554638 · Columbia University
2026-08-07 – 2030-04 · Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
What this study did
NCT07900074 · McMaster University
2026-10-31 – 2029-12-31 · Obesity (Disorder)
What this study did
NCT07715929 · Yunlong Wang
2026-09-01 – 2029-12-30 · Atrial Fibrillation, Obesity & Overweight, Catheter Ablation
What this study did
NCT07630454 · Yunlong Wang
2026-08-01 – 2029-12-01 · Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF), Tirzepatide
What this study did
NCT07326111 · University of Bonn
2025-12-09 – 2029-12 · Polycystic Ovary Syndrome (PCOS), Obesity & Overweight
What this study did
NCT06606821 · Tina Vilsbøll
2024-10-01 – 2028-08-01 · Coronary Artery Disease, Coronary Microvascular Dysfunction, Overweight or Obesity, Stable Angina Pectoris, Chronic Coronary Artery Disease, Atherosclerosis Cardiovascular Disease
What this study did
NCT07096908 · Dasman Diabetes Institute
2025-07-31 – 2028-08-01 · Type1diabetes, Obesity
What this study did
NCT06854614 · The Cleveland Clinic
2025-03-01 – 2028-04-28 · Obesity
What this study did
NCT07257484 · Weill Medical College of Cornell University
2026-06-08 – 2028-02-25 · Obesity (Disorder), Breast Cancer
What this study did
NCT07354880 · University Medical Centre Ljubljana
2026-01-20 – 2027-12-31 · Obesity & Overweight, Adult Congenital Heart Disease
What this study did
NCT06861439 · Wake Forest University Health Sciences
2025-07-07 – 2027-12-31 · Obesity
What this study did
NCT06803888 · Ali Aminian
2025-01-29 – 2027-12-01 · Obesity and Obesity-related Medical Conditions
What this study did
NCT07707778 · National Taiwan University Clinical Trial Center
2026-06-25 – 2027-12 · Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease, Dyslipidaemia, Diabetes Mellitus, Obesity & Overweight, Metabolic Syndrome
What this study did
NCT07893457 · Mayo Clinic
2026-10-26 – 2027-10-26 · Obese Adults
What this study did
NCT07218445 · Mayo Clinic
2026-04-08 – 2027-09-18 · Obesity, Menopause Hot Flashes
What this study did
NCT07588438 · Las Rías Medical Center
2026-07-27 – 2027-08-10 · Obesity, Diabetes Mellitus, Type 2
What this study did
NCT07438444 · Eli Lilly and Company
2026-02-27 – 2027-07 · Diabetes Mellitus, Type 2, Obesity, Overweight
What this study did
NCT07154719 · Pennington Biomedical Research Center
2025-10-09 – 2027-05-01 · Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect
What this study did
NCT07057310 · Mayo Clinic
2025-05-01 – 2027-03-31 · Obesity, Menopause
What this study did
NCT06721507 · Marlene Starr
2025-03-27 – 2026-12-31 · Obesity and Obesity-related Medical Conditions, Bariatric Surgery
What this study did
NCT06901245 · Grace Kim
2025-05-01 – 2026-12 · Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
What this study did
NCT07423247 · Shahid Beheshti University of Medical Sciences
2026-01-01 – 2026-09 · Tirzepatide
What this study did
NCT06009653 · Washington University School of Medicine
2023-09-13 – 2024-05-29 · Obesity, Metabolic Disease
What this study did
Psoriasis
Psoriatic Arthritis
NCT06864026 · Eli Lilly and Company
2025-03-06 – 2027-08 · Psoriatic Arthritis, Overweight or Obesity
What this study did
Early phase / not applicable (17)
Obesity
NCT06885736 · Dasman Diabetes Institute
2025-08-07 – 2029-12-31 · Obesity
What this study did
NCT07574723 · Dasman Diabetes Institute
2026-05-15 – 2029-12-31 · Obesity
What this study did
NCT07589322 · Tri-Service General Hospital (TSGH)
2026-03-31 – 2029-09-30 · Obesity and Metabolic Syndrome
What this study did
NCT07387796 · The University of Texas at Dallas
2026-10 – 2029-02 · Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
What this study did
NCT07364175 · Cambridge University Hospitals NHS Foundation Trust
2026-01 – 2029-01 · Hypertension, Obesity & Overweight
What this study did
NCT07382024 · National Taiwan University Hospital
2026-06-16 – 2028-07-31 · Atrial Fibrillation Ablation, Persistent Atrial Fibrillation, Obesity & Overweight
What this study did
NCT07728318 · Akhtar Saeed Medical and Dental College
2027-12-12 – 2028-05-12 · Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
What this study did
NCT07633639 · China-Japan Friendship Hospital
2026-05-01 – 2028-05-01 · Obesity
What this study did
NCT07866183 · National Medical Research Center for Therapy and Preventive Medicine
2026-06-29 – 2027-08 · Class I Obesity
What this study did
NCT07293325 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-06-02 – 2027-06-02 · Adults With Simple Obesity
What this study did
NCT07685834 · Sofwave Medical LTD
2026-02-27 – 2027-03-01 · Lax Skin
What this study did
NCT07373834 · University Medical Centre Ljubljana
2026-01 – 2027-03 · Obesity (Disorder)
What this study did
NCT06484114 · Fractyl Health Inc.
2024-09-01 – 2027-02-26 · Obesity, Weight Change Trajectory, Weight Change, Body
What this study did
NCT07740291 · Texas Tech University
2025-01-02 – 2026-12-07 · Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
What this study did
NCT07319975 · Istanbul Galata University
2025-12-29 – 2026-12 · Obesity
What this study did
NCT07176663 · Shahid Beheshti University of Medical Sciences
2026-02-01 – 2026-05-01 · Obesity
What this study did
Psoriatic Arthritis
NCT07443956 · NHS Greater Glasgow and Clyde
2026-03-09 – 2030-05 · Psoriatic Arthritis (PsA), Obesity & Overweight
What this study did
Used as active comparator (16)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Obesity
NCT07845500 · Pfizer
2026-09-30 – 2028-02-16 · Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
What this study did
NCT06662383 · Eli Lilly and Company
2024-11-01 – 2026-12 · Obesity
What this study did
NCT06131437 · Novo Nordisk A/S
2023-11-27 – 2026-01-09 · Obesity
What this study did
Phase 2 (7)
Obesity
NCT05933499 · Massachusetts General Hospital
2025-11-05 – 2029-03-31 · Obesity
What this study did
NCT07521631 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2026-03-31 – 2027-07-23 · Obesity
What this study did
NCT06643728 · Eli Lilly and Company
2024-10-21 – 2026-10-27 · Obesity, Overweight
What this study did
NCT06737042 · Gan and Lee Pharmaceuticals, USA
2025-02-24 – 2026-02-27 · Obesity and Overweight
What this study did
NCT06911203 · BrightGene Bio-Medical Technology Co., Ltd.
2025-04-09 – 2026-01-14 · Obesity
What this study did
NCT06326060 · Novo Nordisk A/S
2024-03-18 – 2025-05-01 · Obesity
What this study did
Phase 1/2 (3)
Obesity
NCT06700538 · Arrowhead Pharmaceuticals
2024-12-04 – 2028-02-15 · Obesity
What this study did
NCT07000955 · Innovent Biologics (Suzhou) Co. Ltd.
2025-06-17 – 2027-05-14 · Obesity
What this study did
Phase 1 (1)
Obesity
NCT07842640 · Ascletis Pharma (China) Co., Limited
2026-08-27 – 2027-06 · Chronic Weight Management
What this study did
Phase 4 (2)
Obesity
NCT07555730 · Huazhong University of Science and Technology
2026-04-30 – 2028-09-30 · Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance
What this study did
NCT07697391 · The First Affiliated Hospital of Anhui Medical University
2026-07-16 – 2028-01-31 · Obesity, Diabetes Mellitus, Type 2
What this study did
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Obesity
NCT07943754 · Wake Forest University Health Sciences
2027-06 – 2031-11 · Obesity
What this study did
NCT07298915 · University of Virginia
2026-08 – 2027-06 · Obesity & Overweight
What this study did
Phase 2 (1)
Obesity
NCT06445075 · Scholar Rock, Inc.
2024-05-21 – 2025-06-17 · Overweight and Obesity
What this study did
Phase 4 (1)
Obesity
NCT07777575 · Technical University of Munich
2026-10-07 – 2027-08-31 · Obesity (BMI>30)
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Crohn's Disease: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tirzepatide (Zepbound): this drugPhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg)
NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol).
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)ApprovedSmall moleculeGlucocorticoid receptorWeak signalFeatured results are safety only in this race
Budesonide (Ortikos)
ApprovedUS marketing discontinued
—Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signal
NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed
NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34)
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine)
NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab)
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinPartial signal
NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1))
NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1))
Tirzepatide (Mounjaro)
Approved(overall)
PeptideGLP-1/GIP receptor (dual)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w)
NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg))
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinPartial signal
NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed
AfimkibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 3Cell therapyAllogeneic MSC therapyPartial signalNo reviewed efficacy summary in this indication
TH-SC01Phase 3Cell therapyMesenchymal stem cells (MSC)Weak signalNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 2/3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorPartial signal
NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed
AVB-114Phase 2Cell therapyImplantable cell/biomaterial constructPartial signal
NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29).
AZD7798Phase 2Monoclonal antibodyCCR9Weak signalFeatured results are safety only in this race
ExoFloPhase 2Cell therapyMSC-derived exosomesWeak signalFeatured results are safety only in this race
Golimumab (Simponi)Phase 2Monoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 2Small moleculemiR-124not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
EcoActivePhase 1/2Microbiome therapeuticBacteriophage (anti-AIEC)not yet gradedNo reviewed efficacy summary in this indication
Furestem-CDPhase 1/2Cell therapyAllogeneic MSC therapyWeak signalNo reviewed efficacy summary in this indication
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ALLO-ASCPhase 1Cell therapyAdipose-derived MSC therapyWeak signalNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Hemay007Phase 1Small moleculeTNF-alphaWeak signalNo reviewed efficacy summary in this indication
HRS-7085Phase 1Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
KP405
Phase 1(overall)
PeptideGLP-1/GIP receptor (dual)
Partial signal(overall)
No reviewed efficacy summary in this indication
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 63 furthest-along competitors are listed; 10 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(80 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tirzepatide (Zepbound) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (10)
November 2026 (4)
Phase 1ObesityActive not recruiting
Est. primary completion 2026-11 · NCT07299084 · CT.gov ↗
What to watch
Phase 3ObesityActive not recruiting
Est. primary completion 2026-11 · NCT06962280 · CT.gov ↗
What to watch
Phase 3ObesityActive not recruiting
Est. primary completion 2026-11 · NCT06914895 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2026-11-23 · NCT07740291 · CT.gov ↗
What to watch
December 2026 (6)
Phase 1ObesityRecruiting
Est. primary completion 2026-12 · NCT07803744 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2026-12 · NCT07373834 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2026-12-31 · NCT06759701 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2026-12-31 · NCT06802081 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2026-12-31 · NCT06721507 · CT.gov ↗
What to watch
Phase 4ObesityEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07057310 · CT.gov ↗
What to watch
2027 (36)
January 2027 (1)
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-01 · NCT07364175 · CT.gov ↗
What to watch
February 2027 (3)
Phase 4ObesityRecruiting
Est. primary completion 2027-02-01 · NCT07154719 · CT.gov ↗
What to watch
Phase 3ObesityRecruiting
Est. primary completion 2027-02-14 · NCT07481747 · CT.gov ↗
What to watch
Early phase / not applicableObesityActive not recruiting
Est. primary completion 2027-02-15 · NCT06484114 · CT.gov ↗
What to watch
March 2027 (2)
Early phase / not applicableObesityActive not recruiting
Est. primary completion 2027-03-01 · NCT07685834 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-03-20 · NCT06606821 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2ObesityRecruiting
Est. primary completion 2027-04-01 · NCT06811324 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-04-02 · NCT07293325 · CT.gov ↗
What to watch
Phase 1/2ObesityRecruiting
Est. primary completion 2027-04-28 · NCT07463846 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-04-28 · NCT06854614 · CT.gov ↗
What to watch
May 2027 (2)
Phase 4ObesityActive not recruiting
Est. primary completion 2027-05 · NCT06191848 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-05-15 · NCT07292519 · CT.gov ↗
What to watch
June 2027 (3)
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-06 · NCT07866183 · CT.gov ↗
What to watch
Phase 3ObesityNot yet recruiting
Est. primary completion 2027-06-11 · NCT07738276 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2027-06-30 · NCT07354880 · CT.gov ↗
What to watch
July 2027 (3)
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-07 · NCT07671391 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-07 · NCT07438444 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-07-01 · NCT06803888 · CT.gov ↗
What to watch
August 2027 (3)
Phase 4ObesityActive not recruiting
Est. primary completion 2027-08 · NCT06864026 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-08-10 · NCT07588438 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-08-15 · NCT06732245 · CT.gov ↗
What to watch
September 2027 (5)
Phase 1ObesityActive not recruiting
Est. primary completion 2027-09 · NCT06734273 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2027-09 · NCT06143956 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2027-09-01 · NCT06575738 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-09-18 · NCT07218445 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2027-09-30 · NCT06518837 · CT.gov ↗
What to watch
October 2027 (4)
Phase 3ObesityRecruiting
Est. primary completion 2027-10 · NCT06439277 · CT.gov ↗
What to watch
Phase 3ObesityActive not recruiting
Est. primary completion 2027-10 · NCT05556512 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2027-10-26 · NCT07893457 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-10-30 · NCT06861439 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2ObesityRecruiting
Est. primary completion 2027-11 · NCT07228741 · CT.gov ↗
What to watch
December 2027 (5)
Phase 1ObesityActive not recruiting
Est. primary completion 2027-12 · NCT06751589 · CT.gov ↗
What to watch
Phase 4ObesityEnrolling by invitation
Est. primary completion 2027-12 · NCT07707778 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2027-12-01 · NCT06847399 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-12-03 · NCT07257484 · CT.gov ↗
What to watch
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2027-12-31 · NCT07382024 · CT.gov ↗
What to watch
2028 (18)
January 2028 (2)
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2028-01-12 · NCT07728318 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2028-01-31 · NCT06801015 · CT.gov ↗
What to watch
February 2028 (3)
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-02 · NCT07443956 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-02 · NCT07387796 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-02-25 · NCT07096908 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3ObesityRecruiting
Est. primary completion 2028-04 · NCT06937086 · CT.gov ↗
What to watch
May 2028 (3)
Phase 3ObesityRecruiting
Est. primary completion 2028-05 · NCT06937099 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-05 · NCT06857942 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-05-01 · NCT07633639 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2ObesityRecruiting
Est. primary completion 2028-06 · NCT05912621 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1ObesityRecruiting
Est. primary completion 2028-07 · NCT07065552 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2ObesityNot yet recruiting
Est. primary completion 2028-08-15 · NCT07747805 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1ObesityRecruiting
Est. primary completion 2028-09-07 · NCT07868354 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-09-30 · NCT07589322 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2ObesityNot yet recruiting
Est. primary completion 2028-12 · NCT06180616 · CT.gov ↗
What to watch
Phase 3ObesityNot yet recruiting
Est. primary completion 2028-12 · NCT07829198 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-12 · NCT07326111 · CT.gov ↗
What to watch
Phase 2/3ObesityNot yet recruiting
Est. primary completion 2028-12-01 · NCT07846865 · CT.gov ↗
What to watch
2029 (14)
March 2029 (1)
Phase 2ObesityNot yet recruiting
Est. primary completion 2029-03 · NCT07078838 · CT.gov ↗
What to watch
April 2029 (1)
Phase 4ObesityRecruiting
Est. primary completion 2029-04 · NCT07554638 · CT.gov ↗
What to watch
May 2029 (1)
Early phase / not applicableObesityRecruiting
Est. primary completion 2029-05-15 · NCT07574723 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2ObesityRecruiting
Est. primary completion 2029-06-30 · NCT06582875 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4ObesityRecruiting
Est. primary completion 2029-07 · NCT07247084 · CT.gov ↗
What to watch
August 2029 (3)
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-08-01 · NCT07630454 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2029-08-30 · NCT06885736 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2029-08-31 · NCT06517212 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-09-01 · NCT07715929 · CT.gov ↗
What to watch
October 2029 (3)
Phase 3ObesityNot yet recruiting
Est. primary completion 2029-10 · NCT07881432 · CT.gov ↗
What to watch
Phase 3ObesityRecruiting
Est. primary completion 2029-10 · NCT07881458 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2029-10-31 · NCT07349641 · CT.gov ↗
What to watch
December 2029 (2)
Phase 3ObesityRecruiting
Est. primary completion 2029-12 · NCT07817875 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2029-12-31 · NCT07900074 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Phase 2ObesityActive not recruiting
Est. primary completion 2030-02-01 · NCT07693608 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 2ObesityRecruiting
Est. primary completion 2034-12-31 · NCT07874828 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 December 2024ApprovalFDA approves Zepbound for obstructive sleep apnea in adults with obesity
US, FDA · Source ↗